Understanding the biological principles that underlie the mechanisms by which infectious agents adapt to and undermine the defense mechanisms of a host organism is critical for the development of therapeutic agents to fight disease. The LaMontagne Center for Infectious Disease conducts basic and translational research into the molecular mechanisms of pathogenesis of bacterial, viral, parasitic, or fungal infections and strategies for their prophylaxis and therapy. The LaMontagne Center was established at The University of Texas at Austin in November 2013 as the Center for Infectious Disease (CID) and was renamed just over three years later for scientist and public health champion John Ring LaMontagne. The LaMontagne Center, while located within the College of Natural Sciences, is composed of highly interdisciplinary researchers spanning at least four colleges: Natural Sciences, Engineering, Pharmacy, and the Dell Medical School.
Infectious Disease News
Scientists think they may have uncovered a whole new approach to fighting antibiotic-resistant bacteria, which, if successful, would help address a health crisis responsible for more deaths every year than either AIDS or malaria.
Using cellphone mobility data and COVID-19 hospital admissions data, researchers at The University of Texas at Austin have reliably forecast regional hospital demands for almost two years, according to a new study published in the Proceedings of the National Academy of Sciences. The forecasting system, which municipal authorities credit with helping Austin maintain the lowest COVID-19 death rate among all large Texas cities, has been built out for use by 22 municipal areas in Texas and can be used by any city to guide COVID-19 responses as the virus continues to spread.
Expanding rapid testing stands out as an affordable way to help mitigate risks associated with COVID-19 and emerging variants. Infectious disease researchers at The University of Texas at Austin have developed a new model that tailors testing recommendations to new variants and likely immunity levels in a community, offering a new strategy as public health leaders seek a way out of a pandemic that has so far thwarted the best efforts to end its spread. It is the first study to identify optimal levels of testing in a partially immunized population.